New ONCONASE(R) Non-Small Cell Lung Cancer Data Presented at

[dadstimeon]

ISOTT Annual Meeting

http://www.prnewswire.com/cgi-bin/stori ... 549&EDATE=

BLOOMFIELD, N.J., Sept. 6 /PRNewswire-FirstCall/ -- Alfacell Corporation

(Nasdaq: ACEL) a biopharmaceutical company focused on the discovery,

development and commercialization of ribonuclease (RNase) therapeutics for

cancer, today announced that Intae Lee, Ph.D., Department of Radiology,

University of Pennsylvania, presented new data on the effectiveness of

ONCONASE against non-small cell lung cancer (NSCLC) at the 33rd Annual Meeting

of the International Society on Oxygen Transport to Tissue (ISOTT) held from

August 28 through September 1 in Brisbane, Australia. Dr. Lee's presentation

was entitled, 'Possible Mechanisms of Improved Radiation Response by the

Cytotoxic RNase, ONCONASE®, on A549 Human Lung Cancer Xenografts of nude

Mice.'

"Our current studies illustrate the remarkable effect of ONCONASE as a

single agent against NSCLC," stated Dr. Lee. "Specifically, ONCONASE, when

combined with radiation therapy, was shown to enhance the radiation-

sensitivity to treatment in tumor cells without causing the common

radiation-induced tissue damage to non-tumor cells." Dr. Lee concluded,

"ONCONASE likely enhanced the radiation response of A549 human NSCLC in vitro

and in vivo due to its combined mechanisms of reduced O2 consumption rate,

inhibition of sub-lethal damage repair, induced apoptosis, and temporarily

improved tumor blood flow."

"These studies offer further validation of ONCONASE's unique molecular

mechanisms and potential as a novel and promising treatment for NSCLC," stated

Kuslima Shogen, Chief Executive Officer of Alfacell. "We also believe that

the current suite of data supporting ONCONASE as a potent, efficacious

cytotoxic agent against non-small cell lung carcinoma and other solid tumors

will continue to expand."

About Alfacell Corporation

Alfacell Corporation is a biopharmaceutical company focused on the

discovery, development and commercialization of novel therapeutics for cancer,

using its proprietary ribonuclease (RNase) technology platform. ONCONASE®

(ranpirnase), Alfacell's lead investigational drug candidate, is currently

being evaluated in several studies, including a Phase IIIb trial for malignant

mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer

(NSCLC). For more information, please visit http://www.alfacell.com .

About Non-Small Cell Lung Cancer (NSCLC)

According to the American Cancer Society, lung cancer is the leading cause

of cancer deaths worldwide among men and women. NSCLC is the most common form

of lung cancer, accounting for 80 percent of all lung cancer cases. In 2004,

NSCLC accounted for approximately 160,000 deaths in the United States.

According to industry analysts, the NSCLC drug market is projected to exceed

$4 billion by 2012.

This press release includes statements that may constitute "forward-

looking" statements, usually containing the words "believe," "estimate,"

"project," "expect" or similar expressions. Forward-looking statements involve

risks and uncertainties that could cause actual results to differ materially

from the forward-looking statements. Factors that would cause or contribute to

such differences include, but are not limited to, uncertainties involved in

transitioning from concept to product, uncertainties involving the ability of

the Company to finance research and development activities, potential

challenges to or violations of patents, uncertainties regarding the outcome of

clinical trials, the Company's ability to secure necessary approvals from

regulatory agencies, dependence upon third-party vendors, and other risks

discussed in the Company's periodic filings with the Securities and Exchange

Commission. By making these forward-looking statements, the Company undertakes

no obligation to update these statements for revisions or changes after the

date of this release.

Contact:

Alfacell Corporation: Investor/Media Relations:

Kuslima Shogen Elite FinancialCommunications

Robert Love Stephanie Noiseux

(973) 748-8082 (407) 585-1080

info@alfacell.com acel@efcg.net